BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35246585)

  • 1. Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study.
    Liu W; Han Y
    Sci Rep; 2022 Mar; 12(1):3597. PubMed ID: 35246585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.
    Xu H; Han Y; Wu Y; Wang Y; Wang J; Xu B
    Cancer Med; 2022 Dec; 11(23):4501-4512. PubMed ID: 35598300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort.
    Luo C; Zhong X; Wang Z; Wang Y; Wang Y; He P; Peng Q; Zheng H
    Int J Biol Markers; 2019 Mar; 34(1):41-46. PubMed ID: 30852974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.
    Han Y; Wu Y; Xu H; Wang J; Xu B
    Int J Clin Oncol; 2022 Apr; 27(4):707-716. PubMed ID: 35041101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a Predictive Model to Predict Survival of de Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis.
    Li M; Liu M; Zhu L; Lu H; Mao A; Liu H; Yu K; Dong L
    Discov Med; 2023 Jun; 35(176):283-292. PubMed ID: 37272095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
    Zhao W; Wu L; Zhao A; Zhang M; Tian Q; Shen Y; Wang F; Wang B; Wang L; Chen L; Zhao X; Dong D; Zhang L; Yang J
    BMC Cancer; 2020 Oct; 20(1):982. PubMed ID: 33046035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
    Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
    Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study.
    Huang Z; Hu C; Liu K; Yuan L; Li Y; Zhao C; Hu C
    BMC Cancer; 2020 Nov; 20(1):1145. PubMed ID: 33238981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study.
    Xiong Y; Cao H; Zhang Y; Pan Z; Dong S; Wang G; Wang F; Li X
    World Neurosurg; 2019 Aug; 128():e823-e834. PubMed ID: 31096027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Subtypes and Mortality of Breast Cancer Patients With Brain Metastasis at Diagnosis: A Population-Based Study.
    He DJ; Yu DQ; Wang QM; Yu ZY; Qi YH; Shao QJ; Chang H
    Inquiry; 2021; 58():469580211055636. PubMed ID: 34789038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.